Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

QUOTED. 10 May 2019. Mike Roman.

Executive Summary

Industrial conglomerate 3M is paying $6.7bn to buy Acelity LP and its KCI subsidiaries in an ambitious move to expand its presence in the wound-care market. See what 3M CEO Mike Roman said about it here.

"Today, our advanced wound-care technologies include solutions that prevent the formation of wounds, prepare the wound for the beginning of the healing process and protect the wound while it heals. This acquisition will help us to build out these solutions and expand our offerings, enabling us to provide greater value across the entire care pathway for patients and healthcare providers. It will also allow us to apply our fundamental strengths to create unique value, especially around our global reach and technology development." – Mike Roman, CEO, 3M

Click here for a free trial of Medtech Insight

 
Advertisement

Related Content

3M Aims For Acelity In $6.7Bn Deal To Expand Wound-Care Presence

Topics

Advertisement
UsernamePublicRestriction

Register

MT125077

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel